DRG Market Assessment reports
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Alzheimer’s Disease – Access & Reimbursement – Access & Reimbursement – Alzheimer’s Disease (US)
Eisai / Biogen’s Leqembi (lecanemab) and Eli Lilly’s Kisunla (donanemab) are vying to capitalize on the potential for a disease-modifying therapy (DMT) in Alzheimer’s disease (AD), and…
Myelodysplastic Syndromes – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders, which result in cytopenia and an increased risk of progression to acute myeloid leukemia (AML)…